Comparing of Applied Genetic Technologies Corporation (AGTC) and Onconova Therapeutics Inc. (NASDAQ:ONTX)

Applied Genetic Technologies Corporation (NASDAQ:AGTC) and Onconova Therapeutics Inc. (NASDAQ:ONTX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Applied Genetic Technologies Corporation 3 0.00 11.34M 0.10 39.39
Onconova Therapeutics Inc. N/A 0.00 8.00M -4.33 0.00

In table 1 we can see Applied Genetic Technologies Corporation and Onconova Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation 385,635,584.57% 2.2% 1.7%
Onconova Therapeutics Inc. 1,594,578,433.33% -301.5% -111.8%

Volatility & Risk

Applied Genetic Technologies Corporation’s volatility measures that it’s 151.00% more volatile than Standard & Poor’s 500 due to its 2.51 beta. Onconova Therapeutics Inc. on the other hand, has 2.69 beta which makes it 169.00% more volatile compared to Standard & Poor’s 500.

Liquidity

The current Quick Ratio of Applied Genetic Technologies Corporation is 10.9 while its Current Ratio is 10.9. Meanwhile, Onconova Therapeutics Inc. has a Current Ratio of 1.3 while its Quick Ratio is 1.3. Applied Genetic Technologies Corporation is better positioned to pay off its short-term and long-term debts than Onconova Therapeutics Inc.

Analyst Ratings

Applied Genetic Technologies Corporation and Onconova Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 0 3 3.00
Onconova Therapeutics Inc. 0 0 1 3.00

Applied Genetic Technologies Corporation’s average target price is $9.5, while its potential upside is 227.59%. Meanwhile, Onconova Therapeutics Inc.’s average target price is $12, while its potential upside is 3,815.17%. Based on the analysts view we can conclude, Onconova Therapeutics Inc. is looking more favorable than Applied Genetic Technologies Corporation.

Insider & Institutional Ownership

Applied Genetic Technologies Corporation and Onconova Therapeutics Inc. has shares held by institutional investors as follows: 55.1% and 49.3%. Insiders held roughly 0.5% of Applied Genetic Technologies Corporation’s shares. Competitively, 4.76% are Onconova Therapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Applied Genetic Technologies Corporation -3.98% 4.32% -8.31% 30.41% -5.28% 55.02%
Onconova Therapeutics Inc. 8.7% -12.59% -40.48% 2.46% -61.81% 18.48%

For the past year Applied Genetic Technologies Corporation has stronger performance than Onconova Therapeutics Inc.

Summary

Applied Genetic Technologies Corporation beats Onconova Therapeutics Inc. on 8 of the 11 factors.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companyÂ’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; a license agreement with SymBio Pharmaceuticals Limited; and a strategic collaboration with Cellectar Biosciences, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.